SHH De Novo submitted the IND application of DN1406131 to FDA
Source: Date:2018-01-05
Shanghai De Novo Pharmatech Co., Ltd submitted the Investigational New Drug (IND) application of the DN1406131 to US Food and Drug Administration (FDA) on December 19th, 2017. DN1406131 is an investigational, oral and potent dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan2,3-dioxygenase 2 (TDO2), for cancer immunotherapy.
沪公网安备 31011502005675号